Video - 23 January 2013

2012 BPI Europe Conference Review

Reasons why BPI Europe remains the leading bioprocessing event in Europe

License:: © All rights reserved
The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
File format:: .mov
Length:: 1:11

Topics

Engineering industry

Contacts

Daniel Barry
Press contact Dr BPI Europe Project Manager

Related content

Deal making in the biosimilars market: increasing investment for decreasing return? - DataMonitor
5 February 2013 08:09
Biosimilars are big business. The global biologics market reached $125 billion in 2011, and is predicted to top $150 billion by the end of 2016. Of this, roughly $60 billion will be in off-patent sales.
ADC manufacturing made rapid progress over last five years, says Seattle Genetics
31 January 2013 08:00
Exclusive Interview with Nathan Ihle, Executive Director, Process Chemistry & Analytical Biochemistry, Seattle Genetics, USA
Peter Greenleaf steps down as MedImmune president, Bahija Jallal chosen as replacement
29 January 2013 13:35
Peter Greenleaf is stepping down down as president of Gaithersburg-based biotechnology giant MedImmune, according to a company spokesman, to take the helm of parent company AstraZeneca’s Latin America business.
He will be replaced by Bahija Jallal, who currently serves as MedImmune’s executive vice president of research and development. Jallal joined the company in 2006 as vice president of tra
Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013
3 October 2012 09:00
The pursuit of Biosimilars, Antibody-Drug Conjugates and New Processing Technologies will set the trend for biomanufacturing in 2013; so says research from the industry's leading conference and exhibition, BioProcess International Europe.
Pfizer Will Evaluate Whether to Divide Drug Units, CEO Read Says Drew Armstrong - ©2013 Bloomberg News
5 February 2013 09:00
Jan. 30 (Bloomberg) -- Pfizer Inc., the world’s largest drugmaker, may consider dividing its branded medicines and generic products units into separate businesses, Chief Executive Officer Ian Read said.
Lonza pins future hopes on ADC manufacturing
4 February 2013 17:23
ZURICH, Jan 24 (Reuters) - Swiss specialty chemicals and life sciences group Lonza reported a better than expected rise in profits on Thursday but dampened expectations of another big jump this year, taking the edge off a two-month rally in the share price.
Sartorius Profits Jump 20% driven by growth in bioprocessing
31 January 2013 08:00
Sartorius said today it finished last year with a 20% jump in profits, helped by growing U.S. revenue as well as growth in its bioprocessing, industrial weighing, and lab products and services units.
Sanofi’s Chief Says Investors Underestimate Drug Pipeline - Originally Published in Bloomberg
29 January 2013 15:48
Sanofi (SAN) Chief Executive Officer Chris Viehbacher says investors are still underestimating the French company’s pipeline of experimental drugs.

2012 BPI Europe Conference Review

Topics

Categories

Contacts

Daniel Barry

Related media

Related content